Synthetic derivatives of THC may weaken HIV-1 infection to enhance antiviral therapies

April 30, 2013

A new use for compounds related in composition to the active ingredient in marijuana may be on the horizon: a new research report published in the Journal of Leukocyte Biology shows that compounds that stimulate the cannabinoid type 2 (CB2) receptor in white blood cells, specifically macrophages, appear to weaken HIV-1 infection. The CB2 receptor is the molecular link through which the pharmaceutical properties of cannabis are manifested. Diminishing HIV-1 infection in this manner might make current anti-viral therapies more effective and provide some protection against certain HIV-1 complications.

"The synthetic compounds we used in our study may show promise in helping the body fight HIV-1 infection,'" said Yuri Persidsky, M.D., Ph.D., a researcher involved in the work from the Department of Pathology and Laboratory Medicine at Temple University School of Medicine in Philadelphia, PA. "As compounds like these are improved further and made widely available, we will continue to explore their potential to fight other that are notoriously difficult to treat."

To make this discovery, scientists used a cell culture model to infect human macrophages with HIV-1 and added similar to the active ingredient in marijuana to activate the CB2 receptor. At different times during the infection, samples from the culture were taken to see if the replication of the was decreased. The researchers observed diminished HIV growth and a possible protective effect from some HIV-1 complications.

"HIV/AIDS has posed one of the most significant health challenges in modern medicine," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "Recent high profile vaccine failures mean that all options need to be on the table to prevent or treat this devastating infection. Research on the role of cannabinoid type 2 receptors and viral infection may one day allow targeting these receptors to be part of combination therapies that use exploit multiple weaknesses of the virus simultaneously."

Explore further: Researchers discuss challenges to developing broadly protective HIV vaccines

More information: Servio H. Ramirez, Nancy L. Reichenbach, Shongshan Fan, Slava Rom, Steven F. Merkel, Xu Wang, Wen-zhe Ho, and Yuri Persidsky. Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists. J. Leukoc. Biol. May 2013 93:801-810; doi:10.1189/jlb.1012523

Related Stories

New book on HIV from Cold Spring Harbor Laboratory Press

December 15, 2011

The worldwide AIDS epidemic makes research on HIV, the disease processes it induces, and potential HIV therapies among the most critical in biomedical science. Furthermore, the basic biology of HIV infections provides a model ...

Cancer drug shows promise in eradicating latent HIV infection

November 29, 2012

Breakthrough drugs have made it possible for people to live with HIV longer than ever before, but more work must be done to actually cure the disease. One of the challenges researchers face involves fully eradicating the ...

Recommended for you


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.